Rapport Therapeutics (NASDAQ:RAPP - Get Free Report)'s stock had its "market outperform" rating reaffirmed by research analysts at JMP Securities in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $28.00 target price on the stock. JMP Securities' target price points to a potential upside of 91.78% from the stock's current price.
Separately, Citizens Jmp assumed coverage on Rapport Therapeutics in a report on Tuesday, April 8th. They issued a "mkt outperform" rating on the stock.
View Our Latest Stock Analysis on RAPP
Rapport Therapeutics Trading Down 5.1%
Shares of Rapport Therapeutics stock traded down $0.78 during trading hours on Tuesday, reaching $14.60. The stock had a trading volume of 142,758 shares, compared to its average volume of 165,373. The firm has a 50 day simple moving average of $11.25 and a two-hundred day simple moving average of $12.13. The firm has a market capitalization of $532.90 million and a price-to-earnings ratio of -4.23. Rapport Therapeutics has a 1 year low of $6.43 and a 1 year high of $29.74.
Rapport Therapeutics (NASDAQ:RAPP - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.77) by $0.09. Sell-side analysts forecast that Rapport Therapeutics will post -3.65 EPS for the current year.
Institutional Investors Weigh In On Rapport Therapeutics
Several hedge funds have recently modified their holdings of RAPP. KLP Kapitalforvaltning AS purchased a new stake in shares of Rapport Therapeutics during the 4th quarter valued at about $34,000. Deutsche Bank AG purchased a new stake in shares of Rapport Therapeutics during the 4th quarter valued at about $41,000. Virtus ETF Advisers LLC purchased a new stake in shares of Rapport Therapeutics during the 4th quarter valued at about $66,000. Corebridge Financial Inc. raised its holdings in shares of Rapport Therapeutics by 79.1% during the 1st quarter. Corebridge Financial Inc. now owns 8,271 shares of the company's stock valued at $83,000 after buying an additional 3,653 shares during the period. Finally, Wells Fargo & Company MN raised its holdings in shares of Rapport Therapeutics by 38.9% during the 4th quarter. Wells Fargo & Company MN now owns 4,824 shares of the company's stock valued at $86,000 after buying an additional 1,352 shares during the period.
About Rapport Therapeutics
(
Get Free Report)
Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.
Read More
Before you consider Rapport Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapport Therapeutics wasn't on the list.
While Rapport Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
